Skip to main content Back to Top
Advertisement

5/26/2016

Memantine Hydrochloride Extended-Release Capsules

Reason for the Shortage

    • Actavis states the reason for the shortage of Namenda XR capsules was manufacturing delay.
    • There are several other manufacturers of memantine immediate release tablets and these were not affected by the shortage.

Available Products

    • Namenda XR oral capsule, Actavis, 14 mg, 30 count, NDC 00456-3414-33
    • Namenda XR oral capsule, Actavis, 14 mg, 90 count, NDC 00456-3414-90
    • Namenda XR oral capsule, Actavis, 14 mg, unit-dose 100 count, NDC 00456-3414-63
    • Namenda XR oral capsule, Actavis, 21 mg, 30 count, NDC 00456-3421-33
    • Namenda XR oral capsule, Actavis, 28 mg, 30 count, NDC 00456-3428-33
    • Namenda XR oral capsule, Actavis, 28 mg, 90 count, NDC 00456-3428-90
    • Namenda XR oral capsule, Actavis, 28 mg, unit-dose 100 count, NDC 00456-3428-63
    • Namenda XR oral capsule, Actavis, 7 mg, 30 count, NDC 00456-3407-33
    • Namenda XR oral capsule, Actavis, Titration Pack 28 count, NDC 00456-3400-29

Estimated Resupply Dates

    • Actavis has all Namenda XR presentations available.

Updated

Updated May 26, 2016 by Leslie Jensen, PharmD, Drug Information Specialist. Created February 19, 2014 by Jane Chandramouli, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.